Prestige BioPharma Limited (KRX:950210)
South Korea flag South Korea · Delayed Price · Currency is KRW
13,020
-190 (-1.44%)
At close: Oct 2, 2025

Prestige BioPharma Ratios and Metrics

Millions KRW. Fiscal year is Jul - Jun.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 20212019 - 2020
Period Ending
Oct '25 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21 2019 - 2020
156,490176,683103,966113,582137,620396,635
Upgrade
Market Cap Growth
-4.96%69.94%-8.47%-17.47%-65.30%-
Upgrade
Enterprise Value
224,259210,19744,042-6,736-150,494-63,944
Upgrade
Last Close Price
13020.0014700.008650.009450.0011450.0033000.00
Upgrade
PE Ratio
35.177.92-6.47--
Upgrade
Forward PE
-12.0112.0112.0112.01-
Upgrade
PS Ratio
10.9212.33150.88701.81--
Upgrade
PB Ratio
0.310.350.200.210.320.69
Upgrade
P/TBV Ratio
0.420.480.260.280.320.69
Upgrade
EV/Sales Ratio
15.6514.6763.92---
Upgrade
Debt / Equity Ratio
0.280.280.170.210.010.01
Upgrade
Debt / EBITDA Ratio
---9.11--
Upgrade
Asset Turnover
0.020.020.000--
Upgrade
Inventory Turnover
1.181.180.890.01--
Upgrade
Quick Ratio
1.051.051.532.247.2632.70
Upgrade
Current Ratio
1.271.271.722.317.4632.74
Upgrade
Return on Equity (ROE)
0.81%0.81%-10.38%-0.59%-42.08%-2.07%
Upgrade
Return on Assets (ROA)
-5.71%-5.71%-5.35%0.10%-13.89%-3.01%
Upgrade
Return on Capital (ROIC)
-6.62%-6.62%-6.14%0.12%-15.08%-3.18%
Upgrade
Return on Capital Employed (ROCE)
---0.20%--
Upgrade
Earnings Yield
14.25%12.62%-31.66%15.47%-153.65%-1.86%
Upgrade
FCF Yield
-59.35%-52.57%-65.49%-95.65%-74.36%-4.13%
Upgrade
Buyback Yield / Dilution
-0.44%-0.44%0.22%--16.46%-20.98%
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.